Novacyt reports 900% increase in first-half sales
Clinical diagnostics firm Novacyt (NYCT:AIM) reported first-half revenues over 900% to €72.4 million and said it expected to see significant on-going demand to continue into 2021. The shares added 3% to 275p and are up 1,800%...
13 July 2020
